A/Prof Luc Furic
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
134 Scholarly works
6 Projects
HIGHLIGHTS
2026
Journal article
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer
DOI: 10.1038/s41467-026-74334-z2026
Journal article
Abstract SY24-02: Di-codon organization links tRNA modifications to cancer cell proteome composition
DOI: 10.1158/1538-7445.am2026-sy24-022026
Journal article
Abstract 427: PMR-116, a second-generation RNA polymerase I inhibitor displaying therapeutic efficacy in a broad spectrum of malignancies.
DOI: 10.1158/1538-7445.am2026-4272026
Journal article
Abstract 601: Translational reprogramming disrupts mitosis to drive SMAD4-deficient esophageal adenocarcinoma.
DOI: 10.1158/1538-7445.am2026-6012023
Research grants (international)
An Accelerated Platform Using Lead-212 Targeted \03b1-Particle Therapy to Radically Improve Cancer Lethality of Prostate Cancer Theranostics Using Novel Targets and Better Understanding of Resistance: The Cancer Lethality Lead Collaboration
2023
Research grants (ARC, NHMRC, MRFF)
Codon Bias and the Role of tRNA Modifications in Cancer
2017
Research Grant
Harnessing Synergies Between 177lutate Therapy and Olaparib to Improve Clinical Outcome of Men With Metastatic Castration Resistant Prostate Cancer
RECENT SCHOLARLY WORKS
2025
Journal article
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
DOI: 10.1016/S1470-2045(25)00559-52025
Journal article
Abstract PR-02: Loss of tumor-intrinsic type I IFN facilitates and predicts bone-metastatic progression in advanced prostate cancer and drives radiotherapeutic resistance
DOI: 10.1158/2326-6074.cimm25-pr-022025
Journal article
77P PMR-116, a second generation ribosome biogenesis inhibitor, displays antitumour activity in a wide range of preclinical cancer models and on-target activity in a phase I trial
DOI: 10.1016/j.esmoop.2025.1054272025
Journal article
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
DOI: 10.1016/S1470-2045(25)00332-82024
Journal article
Editorial Expression of Concern: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer.
DOI: 10.1038/s41388-024-03158-22024
Journal article
Correction: Editorial Expression of Concern: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer.
DOI: 10.1038/s41388-024-03204-z
RECENT PROJECTS
2026
Research grants (other domestic)
Trouble at the Ribosome in C9orf72-Driven Amyotrophic Lateral Sclerosis
2022
Research grants (international)
PMR-116, a Novel Inhibitor of Ribosome Biogenesis With Antitumor Activity in Preclinical Models of Prostate Cancer- Services Agt W Monash